• LAST PRICE
    3.7300
  • TODAY'S CHANGE (%)
    Trending Down-0.1300 (-3.3679%)
  • Bid / Lots
    3.6200/ 19
  • Ask / Lots
    3.9100/ 5
  • Open / Previous Close
    3.8200 / 3.8600
  • Day Range
    Low 3.6500
    High 3.8800
  • 52 Week Range
    Low 1.4200
    High 11.9700
  • Volume
    396,962
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.86
TimeVolumeALDX
09:32 ET34093.845
09:34 ET1003.865
09:38 ET18223.85
09:39 ET18833.8527
09:43 ET1823.88
09:45 ET3003.865
09:48 ET53123.85
09:50 ET68163.83
09:52 ET13863.825
09:54 ET37163.815
09:56 ET2003.815
09:57 ET1003.82
09:59 ET25703.83
10:01 ET11003.83
10:03 ET296043.81
10:06 ET8993.79
10:08 ET3003.81
10:10 ET3003.81
10:12 ET1003.79
10:15 ET3003.81
10:17 ET22133.81
10:19 ET44453.79
10:21 ET6403.79
10:24 ET8003.79
10:26 ET130213.79
10:28 ET7003.7929
10:32 ET37553.774
10:35 ET1003.78
10:37 ET1003.78
10:39 ET1003.78
10:42 ET1003.78
10:46 ET206353.81
10:48 ET3573.81
10:50 ET4003.81
10:55 ET3003.81
10:57 ET6003.81
11:02 ET3053.81
11:04 ET12473.8
11:08 ET1003.805
11:09 ET1003.79
11:11 ET24003.786
11:13 ET12003.79
11:20 ET6003.7778
11:22 ET3003.7751
11:27 ET1013.78
11:29 ET10403.77
11:33 ET4003.77
11:38 ET131523.74
11:40 ET39053.73
11:42 ET44863.735
11:44 ET15613.735
11:45 ET3003.7388
11:47 ET15003.734
11:49 ET3003.7388
11:51 ET299253.72
11:54 ET77113.725
11:56 ET65003.72
12:00 ET1003.72
12:02 ET16963.715
12:09 ET51513.73
12:12 ET3043.725
12:14 ET32773.736
12:16 ET5323.735
12:23 ET5093.73
12:25 ET7503.728
12:30 ET1003.72
12:32 ET1003.73
12:39 ET2353.725
12:43 ET3033.73
12:45 ET6053.73
12:48 ET58513.7
12:50 ET10403.705
12:52 ET1003.705
12:54 ET5003.7053
12:56 ET4903.7083
12:57 ET1003.705
01:01 ET4893.71
01:06 ET1003.71
01:08 ET2003.71
01:10 ET1003.71
01:14 ET8983.71
01:15 ET2003.71
01:19 ET4003.71
01:21 ET1003.705
01:24 ET17033.7
01:32 ET11003.71
01:35 ET14663.715
01:42 ET2003.72
01:44 ET1003.7184
01:48 ET6003.715
01:50 ET1003.72
01:51 ET1003.7244
01:57 ET4333.71
02:00 ET407893.67
02:02 ET10003.68
02:04 ET1003.68
02:09 ET6503.68
02:11 ET24343.68
02:13 ET1003.68
02:15 ET1003.68
02:18 ET19253.67
02:20 ET2003.67
02:22 ET1003.67
02:24 ET1003.67
02:26 ET1003.68
02:27 ET16503.67
02:29 ET2003.67
02:31 ET21003.66
02:33 ET43603.67
02:36 ET8003.665
02:38 ET29233.66
02:40 ET16353.66
02:42 ET4003.66
02:44 ET2263.659
02:45 ET5003.6677
02:47 ET29863.69
02:49 ET8123.6801
02:51 ET1003.69
02:56 ET13003.705
02:58 ET36043.7
03:00 ET11563.7
03:03 ET2623.7
03:05 ET1003.7
03:09 ET3003.705
03:12 ET10003.72
03:18 ET11403.71
03:21 ET5413.71
03:27 ET1003.71
03:30 ET2603.7174
03:36 ET2493.719
03:39 ET4593.715
03:41 ET3003.715
03:43 ET14573.715
03:45 ET3003.72
03:50 ET2123.725
03:52 ET24703.73
03:54 ET61853.72
03:56 ET29293.715
03:57 ET28213.73
03:59 ET37973.73
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesALDX
Aldeyra Therapeutics Inc
221.6M
-7.3x
---
United StatesPYXS
Pyxis Oncology Inc
223.2M
-2.7x
---
United StatesACRV
Acrivon Therapeutics Inc
223.9M
-2.5x
---
United StatesCADL
Candel Therapeutics Inc
216.9M
-5.7x
---
United StatesPRLD
Prelude Therapeutics Inc
214.2M
-2.1x
---
United StatesQTTB
Q32 Bio Inc
222.2M
-0.7x
---
As of 2024-06-15

Company Information

Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.

Contact Information

Headquarters
131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
Phone
781-761-4904
Fax
302-636-5454

Executives

Independent Chairman of the Board
Richard Douglas
President, Chief Executive Officer, Director
Todd Brady
Senior Vice President - Finance, Interim Chief Financial Officer
Bruce Greenberg
Chief Development Officer
Stephen Machatha
Independent Director
Ben Bronstein

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$221.6M
Revenue (TTM)
$0.00
Shares Outstanding
59.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.46
EPS
$-0.51
Book Value
$2.02
P/E Ratio
-7.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.